 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
"Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS.
| Descriptor ID |
D000069480
|
| MeSH Number(s) |
D02.705.429.906.750 D03.383.742.680.245.500.600.750 D03.633.100.759.138.881.750 D13.570.230.329.525.500 D13.570.685.245.500.600.500 D26.310.423
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
- Chemicals and Drugs [D]
- Organic Chemicals [D02]
- Organophosphorus Compounds [D02.705]
- Organophosphonates [D02.705.429]
- Tenofovir [D02.705.429.906]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D02.705.429.906.750]
- Heterocyclic Compounds [D03]
- Heterocyclic Compounds, 1-Ring [D03.383]
- Pyrimidines [D03.383.742]
- Pyrimidine Nucleosides [D03.383.742.680]
- Cytidine [D03.383.742.680.245]
- Deoxycytidine [D03.383.742.680.245.500]
- Emtricitabine [D03.383.742.680.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.383.742.680.245.500.600.750]
- Heterocyclic Compounds, Fused-Ring [D03.633]
- Heterocyclic Compounds, 2-Ring [D03.633.100]
- Purines [D03.633.100.759]
- Adenine [D03.633.100.759.138]
- Tenofovir [D03.633.100.759.138.881]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D03.633.100.759.138.881.750]
- Nucleic Acids, Nucleotides, and Nucleosides [D13]
- Nucleosides [D13.570]
- Deoxyribonucleosides [D13.570.230]
- Deoxycytidine [D13.570.230.329]
- Emtricitabine [D13.570.230.329.525]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.230.329.525.500]
- Pyrimidine Nucleosides [D13.570.685]
- Cytidine [D13.570.685.245]
- Deoxycytidine [D13.570.685.245.500]
- Emtricitabine [D13.570.685.245.500.600]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D13.570.685.245.500.600.500]
- Pharmaceutical Preparations [D26]
- Drug Combinations [D26.310]
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination [D26.310.423]
Below are MeSH descriptors whose meaning is more specific than "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination".
This graph shows the total number of publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in this website by year, and whether "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 0 | 4 | | 2018 | 2 | 0 | 2 | | 2019 | 2 | 0 | 2 | | 2020 | 2 | 1 | 3 | | 2024 | 0 | 1 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination" by people in Profiles.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
-
Patel N, Morris S, Burke L, Chow K, Pacheco D, Anderson P, Stancyzk F, Blumenthal J. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis. Br J Clin Pharmacol. 2024 Oct; 90(10):2360-2365.
-
Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 07 25; 396(10246):239-254.
-
Yager JL, Anderson PL. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opin Drug Metab Toxicol. 2020 Jun; 16(6):463-474.
-
Del Rio C, Armstrong WS. How Much Are We Willing to Pay for Preexposure Prophylaxis in the United States? Ann Intern Med. 2020 05 05; 172(9):623-624.
-
Liu SN, Gufford BT, Lu JBL, Bushman LR, Anderson PL, Bergstrom RF, Desta Z, Gupta SK. Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. Clin Pharmacol Ther. 2020 05; 107(5):1200-1208.
-
Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. PLoS One. 2019; 14(8):e0221281.
-
Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. AIDS Res Hum Retroviruses. 2018 10; 34(10):835-837.
-
Brooks KM, Anderson PL. Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. Clin Pharmacol Ther. 2018 12; 104(6):1056-1059.
-
Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017 12 15; 76(5):501-511.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|